News Investors Careers About Contact Search HEALTH FOOD ENERGY ENVIRONMENT CONSUMER OUR APPROACH Our Approach Process Business Model Integrated Capabilities Core Technologies UltraVector® RheoSwitch® Cell Systems Informatics Cell Processing Antibody Discovery Endometrial Regenerative Cells Agaricus Platform Neurospora Platform Exclusive Channel Collaborations Contact Us Our Approach » Core Technologies Core Technologies Intrexon’s continual process of design-build-test-learn has generated a knowledge base of performance characteristics for individual genetic components, as well as multi-component assemblies in multiple cellular contexts. Utilizing this database and accompanying software tools, Intrexon rapidly designs and constructs single and multi-gene programs with predictable outcomes. Intrexon’s Better DNA® approach is realized through a unique suite of technologies: UltraVector® – operating system behind our biological engineering RheoSwitch® – controlled gene expression Cell Systems Informatics – cell pathway modeling and design LEAP™ – Laser-Enabled Analysis and Processing for purification of cells Antibody Discovery – antigen targeting with fully human antibodies Endometrial Regenerative Cells – Adult-derived stem cells for therapeutic applications Agaricus platform – mushroom-based protein production and trait engineering Neurospora platform – fungal-based protein production Our suite of proprietary and complementary technologies combines the principles of precision engineering with statistical modeling, automation, and large-scale production. These technologies, when leveraged with a growing knowledge base gained from our iterative process, provide our collaborators with a wealth of capabilities – all available in one place. Intrexon is a one-stop shop for start-to-finish conceptualization, engineering, regulation, optimization and production of biologically-based solutions. Our Better DNA® approach gives us a unique advantage over traditional processes in industrial and synthetic biology. IN THE NEWS Histogenics and Intrexon Announce Formation of Exclusive Channel Collaboration for Cartilage Repair Therapies Intrexon and Amneal Expand Relationship with Second Product Collaboration Fibrocell Science and Intrexon Advance GM-HDF-COL7 toward Clinical Development for the Treatment of Recessive Dystrophic Epidermolysis Bullosa Related Documents Tech Platforms for Therapeutics About Intrexon Leadership Our Business History Investor Relations Research IIBR Collaborations Connect Contact Information Public Relations Careers Search Jobs Legal Notices © 2014 Intrexon